Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
Copyright © 2018 Elsevier Inc. All rights reserved..
BACKGROUND: The International mRCC (metastatic renal cell carcinoma) Database Consortium (IMDC) is the standard classification for mRCC. We aimed to evaluate the outcomes of a large cohort of patients with an intermediate or a poor prognosis treated with sunitinib using a different cutoff point for IMDC to improve the classification.
PATIENTS AND METHODS: Patients with an intermediate or a poor prognosis according to the IMDC criteria and treated with sunitinib were included in the present study. A new cutoff point was used to categorize the patients. The new score was validated in an independent cohort of patients.
RESULTS: A total of 457 patients were included in the present study. Significant differences in overall survival (OS) were highlighted regarding the number of prognostic factors. Three categories were identified according to the presence of 1 (ie, favorable-intermediate group), 2 (ie, real-intermediate group), and > 2 (ie, poor group) factors. The corresponding median OS periods were 32.9, 20.0, and 8.9 months, with significant differences among the groups. The validation cohort included 389 patients. The median OS period for the favorable-intermediate group, real-intermediate group, and poor group was 34.3, 19.4, and 9.0 months, respectively, with confirmed significant differences among the groups.
CONCLUSION: Our analysis revealed significant differences among patients with an intermediate prognosis using the IMDC prognostic factors. Further investigations to optimize the use of available and upcoming therapies are required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical genitourinary cancer - 16(2018), 5 vom: 01. Okt., Seite 355-359.e1 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iacovelli, Roberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Intermediate risk |
|---|
| Anmerkungen: |
Date Completed 01.07.2019 Date Revised 01.07.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clgc.2018.04.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM284488968 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM284488968 | ||
| 003 | DE-627 | ||
| 005 | 20231225043330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clgc.2018.04.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0948.xml |
| 035 | |a (DE-627)NLM284488968 | ||
| 035 | |a (NLM)29803346 | ||
| 035 | |a (PII)S1558-7673(18)30151-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iacovelli, Roberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.07.2019 | ||
| 500 | |a Date Revised 01.07.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The International mRCC (metastatic renal cell carcinoma) Database Consortium (IMDC) is the standard classification for mRCC. We aimed to evaluate the outcomes of a large cohort of patients with an intermediate or a poor prognosis treated with sunitinib using a different cutoff point for IMDC to improve the classification | ||
| 520 | |a PATIENTS AND METHODS: Patients with an intermediate or a poor prognosis according to the IMDC criteria and treated with sunitinib were included in the present study. A new cutoff point was used to categorize the patients. The new score was validated in an independent cohort of patients | ||
| 520 | |a RESULTS: A total of 457 patients were included in the present study. Significant differences in overall survival (OS) were highlighted regarding the number of prognostic factors. Three categories were identified according to the presence of 1 (ie, favorable-intermediate group), 2 (ie, real-intermediate group), and > 2 (ie, poor group) factors. The corresponding median OS periods were 32.9, 20.0, and 8.9 months, with significant differences among the groups. The validation cohort included 389 patients. The median OS period for the favorable-intermediate group, real-intermediate group, and poor group was 34.3, 19.4, and 9.0 months, respectively, with confirmed significant differences among the groups | ||
| 520 | |a CONCLUSION: Our analysis revealed significant differences among patients with an intermediate prognosis using the IMDC prognostic factors. Further investigations to optimize the use of available and upcoming therapies are required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Intermediate risk | |
| 650 | 4 | |a Overall survival | |
| 650 | 4 | |a Poor risk | |
| 650 | 4 | |a Sunitinib | |
| 650 | 4 | |a mRCC | |
| 650 | 7 | |a Sunitinib |2 NLM | |
| 650 | 7 | |a V99T50803M |2 NLM | |
| 700 | 1 | |a De Giorgi, Ugo |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Zucali, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Nolè, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Sabbatini, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Fraccon, Anna Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Basso, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mosca, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Atzori, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Santini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Facchini, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Fornarini, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Pasini, Felice |e verfasserin |4 aut | |
| 700 | 1 | |a Masini, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Massari, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Sebastiano |e verfasserin |4 aut | |
| 700 | 1 | |a Sava, Teodoro |e verfasserin |4 aut | |
| 700 | 1 | |a Sacco, Cosimo |e verfasserin |4 aut | |
| 700 | 1 | |a Ricotta, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Sperduti, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Tortora, Giampaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Porta, Camillo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical genitourinary cancer |d 2005 |g 16(2018), 5 vom: 01. Okt., Seite 355-359.e1 |w (DE-627)NLM160229936 |x 1938-0682 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:5 |g day:01 |g month:10 |g pages:355-359.e1 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clgc.2018.04.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 5 |b 01 |c 10 |h 355-359.e1 | ||